Update 2:35pm: Adds Regeneron comment
Sharamand/iStock via Getty Images
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.
"We have considered Regeneron's remaining arguments and find